immune system
• mice challenged with MUC1-expressing tumor cells do not develop IgM or IgG3 responses, and only 1 transgenic mouse showed an IgG1 antibody response, whereas most wild-type mice similarly challenged showed strong MUC1-specific IgM, IgG1, and half showed strong IgG3 responses
• in response to immunization with 5.25 copies of the MUC1 tandem repeat, wild-type mice generate strong responses in the IgM and all IgG isotypes, but transgenic mice show a strong IgM response but only weak IgG subtype responses
|
• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in the anti-MUC1 IgG response compared with un-injected Tg(MUC1)79.24Gend mice
|
• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in MUC1-specific IgM unlike un-injected Tg(MUC1)79.24Gend mice
|
neoplasm
• after injection of B16.9 melanoma cells, transgenic mice develop progressively growing tumors (average tumor volume 1.31 cm2) at day 26 postinjection
• tumor growth is significantly accelerated compared to injected wild-type mice where only 1 mouse had a tumor at 26 days postinjection; majority of wild-type mice have tumors at 34 days with an average volume of 0.11 cmL2
|
hematopoietic system
• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in the anti-MUC1 IgG response compared with un-injected Tg(MUC1)79.24Gend mice
|
• following injection of a cre adenovirus in the ovarian bursa, mice exhibit an increase in MUC1-specific IgM unlike un-injected Tg(MUC1)79.24Gend mice
|